BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25249257)

  • 1. Clinicopathological significance of CXCR4 expression in renal cell carcinoma: a meta-analysis.
    Tang B; Tang F; Li Y; Yuan S; Li B; Wang Z; He S
    Ann Surg Oncol; 2015 Mar; 22(3):1026-31. PubMed ID: 25249257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and prognostic significance of CXCR4 high expression in renal cell carcinoma: A meta-analysis and literature review.
    Si X; Ma J; Yu F; Zhao H; Huang H; Sun YW
    Int J Surg; 2019 Nov; 71():12-18. PubMed ID: 31494331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
    Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
    Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.
    Du Y; Long Q; Guan B; Mu L
    Dis Markers; 2015; 2015():568980. PubMed ID: 26526157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
    Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
    Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of CXCR4 in non-small cell lung cancer.
    Zhou XM; He L; Hou G; Jiang B; Wang YH; Zhao L
    Drug Des Devel Ther; 2015; 9():1349-58. PubMed ID: 25834393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
    Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
    Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival.
    Li X; Huang Y; Xia J; Chen N; Wei Q; Li X; Zhang P; Shen PF; Wang J; Zeng H
    Asian Pac J Cancer Prev; 2011; 12(12):3313-8. PubMed ID: 22471472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
    D'Alterio C; Consales C; Polimeno M; Franco R; Cindolo L; Portella L; Cioffi M; Calemma R; Marra L; Claudio L; Perdonà S; Pignata S; Facchini G; Cartenì G; Longo N; Pucci L; Ottaiano A; Costantini S; Castello G; Scala S
    Curr Cancer Drug Targets; 2010 Nov; 10(7):772-81. PubMed ID: 20578990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
    Zhang C; Li J; Han Y; Jiang J
    Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells.
    Wang L; Huang T; Chen W; Gao X; Zhou T; Wu Z; Sun Y
    Oncol Rep; 2012 Dec; 28(6):2043-8. PubMed ID: 22972438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
    Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
    Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
    Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of Raf-1 kinase inhibitory protein in renal cell carcinoma: a significant prognostic marker.
    Moon A; Park JY; Sung JY; Park YK; Kim YW
    Pathology; 2012 Oct; 44(6):534-9. PubMed ID: 22935977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
    Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
    Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis.
    Bao Y; Wang Z; Liu B; Lu X; Xiong Y; Shi J; Li P; Chen J; Zhang Z; Chen M; Wang L; Wu Z
    Oncogene; 2019 Feb; 38(6):881-895. PubMed ID: 30177838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.